Company news: J&J's Janssen

Share this article:
An Arkansas judge levied a $1.2 billion fine on Johnson & Johnson's Janssen after a jury there found the pharma giant guilty of downplaying the risks of its antipsychotic Risperdal. The fine is far and away the largest in a statewide case, though judges and juries in South Carolina, Louisiana and Texas have ordered the firm to pay more than three-quarters of a billion dollars in Risperdal cases combined. J&J's Ortho-McNeil and Janssen units are operating under at federal Corporate Integrity Agreement related to Topamax marketing abuses.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.